Carlyle and SK Capital to take gene therapy firm bluebird bio private
The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, bluebird stockholders will receive $3 per share in cash.
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
(Reuters) - U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake ...
AlpInvest Secondaries Fund VIII has raised nearly $9.4 billion as of 31 December 2024, according to materials prepared for ...
The Carlyle Group Stock Performance Shares of NASDAQ:CG opened at $53.45 on Wednesday. The business has a fifty day moving average of $52.69 and a 200-day moving average of $48.39. The firm has a ...
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...
Carlyle Group Inc. is looking to asset-based finance as its next big growth opportunity, Chief Operating Officer Lindsay ...
The Carlyle Group has announced the listing of its portfolio company Hexaware Technologies, a global IT services company, on the Bombay Stock Exchange and National Stock Exchange in India. The total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback